CAJ | 학술논문

目的：分析躯体形式障碍患者中枢神经递质的脑涨落图（ET）特点，探讨ET对躯体形式障碍诊治的临床指导意义。方法对36例躯体形式障碍患者（患者组）以及33例正常对照者（正常组）进行脑涨落图检测。分别检测正常对照者以及患者在治疗前、治疗后两周、4周及两个月的脑涨落图。结果患者组6种中枢神经递质实测功率均低于正常组（P<0.05），患者组治疗后两周与治疗前中枢神经递质实测功率差异无统计学意义（P>0.05），患者组治疗后4周、两个月6种中枢神经递质实测功率高于治疗前及治疗后两周（P<0.05）。患者组治疗前、治疗后两周5-HT、DA、NA、Ach 相对功率均低于正常组（P<0.05）；患者组治疗后4周和治疗后两个月的5-HT、DA、NA、Ach相对功率均高于治疗前及治疗后两周（P<0.05）。结论躯体形式障碍患者全脑整体功能下降。予5-HT再摄取抑制剂治疗后临床症状可改善。脑涨落图仪可用来检测躯体形式障碍患者的脑神经递质。
목적：분석구체형식장애환자중추신경체질적뇌창락도（ET）특점，탐토ET대구체형식장애진치적림상지도의의。방법대36례구체형식장애환자（환자조）이급33례정상대조자（정상조）진행뇌창락도검측。분별검측정상대조자이급환자재치료전、치료후량주、4주급량개월적뇌창락도。결과환자조6충중추신경체질실측공솔균저우정상조（P<0.05），환자조치료후량주여치료전중추신경체질실측공솔차이무통계학의의（P>0.05），환자조치료후4주、량개월6충중추신경체질실측공솔고우치료전급치료후량주（P<0.05）。환자조치료전、치료후량주5-HT、DA、NA、Ach 상대공솔균저우정상조（P<0.05）；환자조치료후4주화치료후량개월적5-HT、DA、NA、Ach상대공솔균고우치료전급치료후량주（P<0.05）。결론구체형식장애환자전뇌정체공능하강。여5-HT재섭취억제제치료후림상증상가개선。뇌창락도의가용래검측구체형식장애환자적뇌신경체질。
Objective To analyze the characteristics of the brain neurotransmitters on the patients with somatoform dis-orders disease by encephalofluctuograph technology (ET), discuss the value of ET on the diagnose and treatment of somatoform disorders disease. Methods 36 patients with somatoform disorders (patients group) and 33 normal controls (control group) were selected. The patients encephaloelectrical power signals before the treatment, 2 weeks, 4 weeks and 2 months after the treatment were detected by using encephalofluctuograph technology. Results Compared with the normal group, the powers of six brain neurotransmitters significantly decreased (P<0.05) in the somatoform disorders patients group. There was no significant difference in the powers of six brain neurotransmitters of patients group before and 2 weeks after treatment (P>0.05). Compared with the patients group before the treatment and 2 weeks after the treatment , the powers of six brain neurotransmitters were sig-nificantly higher (P<0.05) in the patients group 4 weeks and 2 months after the treatment. Compared with the normal group, the relative power of 5-HT,DA,NA, Ach significantly decreased (P<0.05) in the somatoform disorders patients group before the treatment and 2 weeks after the treatment (P<0.05). Compared with the patients group before the treatment and 2 weeks after the treatment, the relative power of 5-HT, DA, NA, Ach were significantly higher (P<0.05) in the patients group 4 weeks and 2 months after the treatment (P<0.05). Conclusion The whole-brain activity of the somatoform disorders patients decrease. The patients′clinical symptom can be improved by SSRIs treatment. The powers of brain neurotransmitters on the patients with somatoform disorders disease can be detected by using the encephalofluctuograph technology.